This is a summary of the European public assessment report (EPAR) for Nyxoid. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Nyxoid. For practical information about using Nyxoid, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.
Therapeutic Area (MeSH)
ATC Code
V03AB15
ATC Item
naloxone
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Naloxone hydrochloride dihydrate | N/A | Naloxone Hydrochloride/Pentazocine Hydrochloride |
| naloxone hydrochloride dihydrate | N/A | Naloxone Hydrochloride/Pentazocine Hydrochloride |
EMA Name
Nyxoid
Medicine Name
Nyxoid
Aliases
N/A
